Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Bluejay Diagnostics Inc (BJDX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/17/2025: BJDX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -25.89% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.42M USD | Price to earnings Ratio 0.01 | 1Y Target Price 256 |
Price to earnings Ratio 0.01 | 1Y Target Price 256 | ||
Volume (30-day avg) - | Beta 0.38 | 52 Weeks Range 1.46 - 37.50 | Updated Date 06/29/2025 |
52 Weeks Range 1.46 - 37.50 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 277.2 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -80.05% | Return on Equity (TTM) -200.56% |
Valuation
Trailing PE 0.01 | Forward PE - | Enterprise Value -508155 | Price to Sales(TTM) 54.99 |
Enterprise Value -508155 | Price to Sales(TTM) 54.99 | ||
Enterprise Value to Revenue 5.67 | Enterprise Value to EBITDA -0.1 | Shares Outstanding 1494180 | Shares Floating 1125089 |
Shares Outstanding 1494180 | Shares Floating 1125089 | ||
Percent Insiders 0.26 | Percent Institutions 2.48 |
Upturn AI SWOT
Bluejay Diagnostics Inc
Company Overview
History and Background
Bluejay Diagnostics, Inc. is a company focused on developing and marketing point-of-care diagnostic products. Founded with the goal of improving healthcare outcomes through rapid testing, they concentrate on acute care settings.
Core Business Areas
- Point-of-Care Diagnostics: Bluejay Diagnostics develops and aims to market rapid, point-of-care diagnostic tests for various medical conditions.
- Sepsis Testing: Their primary focus has been on developing a rapid sepsis test to improve diagnosis and treatment of this life-threatening condition.
Leadership and Structure
Information on the specific leadership team and organizational structure is limited in easily accessible public sources. Typically, a company of this nature would have a CEO, CFO, and a board of directors.
Top Products and Market Share
Key Offerings
- Sepsis Test: Bluejay Diagnostics' lead product is a rapid point-of-care sepsis test aimed at improving the speed and accuracy of sepsis diagnosis. Market share data is unavailable, given the product is still in development and not yet commercially available. Competitors in sepsis diagnostics include Roche (RHHBY), bioMu00e9rieux (BIM.PA), and Thermo Fisher Scientific (TMO).
Market Dynamics
Industry Overview
The point-of-care diagnostics market is growing rapidly, driven by the need for faster and more convenient diagnostic testing. Factors contributing to this growth include increasing demand for rapid results, rising prevalence of infectious diseases, and advancements in diagnostic technologies.
Positioning
Bluejay Diagnostics aims to position itself as a key player in the point-of-care diagnostics market, specifically in the sepsis testing segment. Their competitive advantage is expected to be speed and accuracy of their test.
Total Addressable Market (TAM)
The total addressable market for sepsis diagnostics is estimated to be in the billions of dollars. Bluejay Diagnostics is positioning itself to capture a portion of this TAM with its rapid point-of-care test. Actual TAM capture depends on regulatory approval and market penetration.
Upturn SWOT Analysis
Strengths
- Potential for rapid and accurate sepsis diagnosis
- Focus on a critical unmet need in healthcare
- Point-of-care testing capabilities
Weaknesses
- Limited financial resources
- Reliance on regulatory approval
- Limited commercial infrastructure
- Significant competition from established players
Opportunities
- Expanding point-of-care diagnostics market
- Increasing awareness of sepsis
- Potential for partnerships with hospitals and healthcare providers
- Government initiatives to improve sepsis management
Threats
- Regulatory hurdles
- Competition from established diagnostic companies
- Technological advancements by competitors
- Clinical trial failures
Competitors and Market Share
Key Competitors
- RHHBY
- BIM.PA
- TMO
Competitive Landscape
Bluejay Diagnostics faces significant competition from larger, more established diagnostic companies. Its success depends on differentiating its sepsis test through superior speed, accuracy, or cost-effectiveness.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is minimal due to the company's development stage.
Future Projections: Future growth is dependent on regulatory approval and commercialization of their sepsis test. Projections are highly speculative at this stage.
Recent Initiatives: Recent initiatives likely involve ongoing clinical trials and regulatory submissions for their sepsis test.
Summary
Bluejay Diagnostics is a high-risk, high-reward development-stage company focused on point-of-care sepsis diagnostics. Its success hinges on regulatory approval and successful commercialization of its test. It faces intense competition and has limited financial resources, but has the potential to address a significant unmet need in healthcare. Bluejay Diagnostics needs to secure more funding to bring their product to the market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- Public filings
- Market research reports
- Analyst reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made based on individual risk tolerance and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bluejay Diagnostics Inc
Exchange NASDAQ | Headquaters Acton, MA, United States | ||
IPO Launch date 2021-11-10 | Principal Financial, Accounting & Executive Officer, President, CEO and Director Mr. Indranil Dey | ||
Sector Healthcare | Industry Medical Devices | Full time employees 7 | Website https://bluejaydx.com |
Full time employees 7 | Website https://bluejaydx.com | ||
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. The company offers the Symphony platform, a technology platform comprising the Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and the Symphony Cartridge, which includes reagents and components. It also provides the ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, the company develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings. Further, it is developing additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.